Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070159 | 0.79 | POLB (0.30) | GAAPOLB | |
| SCHEMBL3641920 | 0.78 | KDM4E (0.44) | NPC1RAB9AKDM4EMAPTNPSR1 | |
| SCHEMBL1223850 | 0.78 | KMT2A (0.40) | NPC1RAB9AKDM4EMAPTKMT2A | |
| SCHEMBL985142 | 0.71 | KMO (0.39) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL30528409 | 0.71 | KMO (0.39) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL9196203 | 0.71 | KMO (0.54) | NPC1RAB9AKDM4EMAPTLMNA | |
| SCHEMBL31224327 | 0.70 | BAZ2B (0.47) | NPC1RAB9AGAAPOLB | |
| SCHEMBL113085 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL2192452 | 0.69 | KMO (0.53) | NPC1RAB9AKDM4EMAPTLMNA | |
| SCHEMBL31191303 | 0.69 | CLK1 (0.35) | RAB9AKDM4EMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
| US-4144339-A | TREATMENT OF BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1979-03-13 | — | — | US | disclosed |
| US-4138487-A | NEMATOCIDES | RHONE-POULENC INDUSTRIES (FR) | 1979-02-06 | — | — | US | disclosed |
| US-4110450-A | BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | DHFR, TYMS, DPYD | NPC1 2880/4885RAB9A 3879/4885KDM4E 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.